The Skopin pharmaceutical factory has the capacity
to produce additional 700 million tablets
and 500 million capsules a year.
In addition, the company is building one more high-tech production
facility to manufacture cytostatic drugs and a wide range
of liquid drugs.
In collaboration with the Krug Dobra charity fund (it provides drugs for those of Russian patients who suffer from the orphan diseases), Skopinpharm delivers the drugs requiring special storage and transportation conditions.
To meet the temperature requirements, the drugs are transported to medical institutions in boxes with GPS trackers and thermal sensors.
Our suppliers (suppliers of materials, services and contract manufacturers) play an important role, because they allow us to maintain sustainable growth and overall success.
We expect suppliers to clearly recognize and adhere to the principles contained in the attached document. The PSCI Principles.pdf
The company makes secondary packaging for the following medications:
- coated and uncoated tablets, including cytostatics;
- capsules;
- injectable dosage forms, incl. blood products;
- liquid drugs.
The secondary packaging of cytostatics, monoclonal antibodies, and hormonal drugs is done in separate rooms. In these rooms, there are transfer hatches, separate ventilation systems, and airlocks for personnel.
The Company implements the Quality Management System that ensures
high quality of products. This system is based on the requirements
of the modern standards:
- GOST ISO 9001-2015 Quality management systems. Requirements,
- The Eurasian Economic Commission resolution
No. 77 dated November 3, 2016 On the Adoption of the Rules of Good
Manufacturing Practice of the Eurasian Economic Union, - The Ministry of Industry and Trade of the Russian Federation order
No. 916 dated June 14, 2013 On Approval of Good
Manufacturing Practices.
The automated engineering system continuously maintains the required cleanliness level, air exchange rate, temperature, moisture, and air pressure for production and auxiliary facilities.
The factory is equipped with the up-to-date facilities from the world's leading manufacturers: Bosch (Germany), Freund-Vector (USA), IMA (Italy), and Kilian (Germany).
The company regularly upgrades its facilities and premises to exactly recreate the technologies required for producing unique drugs.
With the Quality Control System in place, the Skopinpharm factory ensures inspection of the raw materials and all the auxiliary substances, control of the production process and its sanitary conditions, laboratory confirmation of the quality of the manufactured drugs, managing documents properly, and functioning of the personnel training system.
Skopinpharm successfully undergoes annual audits by international pharmaceutical companies, receives positive feedback from consumers, and by far, has never received any claims or complaints from the regulatory authorities.
Skopinpharm manufactures drugs under Special Investment Contracts (SPIC) uniting big investors, manufacturers, and the state. In 2018, the Skopinpharm company signed the SPIC for producing 10 unique products to treat hematological diseases. In 2021, the Company signed the SPIC 2.0 for integrating technologies to produce several unique drugs and some equipment designed to diagnose and treat oncological diseases.
Skopinpharm has a long-term experience of collaboration with the Russian and international companies: Aspen, Novartis, Octapharma Nordic AB, STADA, and others.